Presentation is loading. Please wait.

Presentation is loading. Please wait.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Published byHarvey O’Neal’ Modified over 5 years ago

Similar presentations

Presentation on theme: "FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis."— Presentation transcript:

1 FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma 
Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis Ravetti, MD  Journal of Thoracic Oncology  Volume 12, Issue 8, Pages e116-e118 (August 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 ROS1, anaplastic lymphoma receptor tyrosine kinase gene (ALK), and MNNG HOS Transforming gene (MET) status in malignant pleural mesothelioma (MPM). ROS1 gene rearrangement was investigated by fluorescence in situ hybridization (FISH) with a Spectrum Green Probe (Abbott Molecular, Des Plaines, IL) and Vysis 6q22 ROS1 Break Apart FISH Probe (Abbott Molecular). ALK gene rearrangement was investigated by FISH with a Vysis LSI ALK Dual-Color Break Apart Rearrangement Probe (Abbott Molecular). A cell with normal expression of ROS1 or ALK shows fused red and green signals as a unique yellow signal or as two red and green distinct signals close to each other. In contrast, in the case of translocation of ALK (ROS1), the signals are separated by a gap. White arrows indicate the spot signals in the nucleus for ROS1 or ALK gene, respectively. (A and B) Epthelioid mesothelioma without ROS1 chromosomal translocation. (C and D) Epthelioid mesothelioma without ALK chromosomal translocation. (E and F) Positive control NSCLC with ROS1 chromosomal translocation. (G and H) Positive control NSCLC with ALK translocation. (A, C, E, and G) FISH gene (original magnification, ×100). (B, D, F, and H) Hematoxylin and eosin (original magnification, ×20). Journal of Thoracic Oncology  , e116-e118DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis."

Similar presentations

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.

New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Similar presentations

Ads by Google